Tea Lund Laursen1, Cecilie Brøckner Siggard1, Konstantin Kazankov1, Thomas Damgaard Sandahl1, Holger Jon Møller2, Adrian Ong3, Mark W Douglas3, Jacob George3, Britta Tarp4, Lena Hagelskjaer Kristensen5, Alex Lund Laursen6, Akira Hiramatsu7, Takashi Nakahara7, Kazuaki Chayama7,8, Henning Grønbaek1. 1. a Department of Hepatology & Gastroenterology , Aarhus University Hospital , Aarhus , Denmark. 2. b Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus , Denmark. 3. c Storr Liver Centre , Westmead Institute for Medical Research, Westmead Hospital and University of Sydney , Sydney , Australia. 4. d Diagnostic Centre , Silkeborg Regional Hospital , Silkeborg , Denmark. 5. e Department of Medicine , Viborg Regional Hospital , Viborg , Denmark. 6. f Department of Infectious Diseases , Aarhus University Hospital , Aarhus , Denmark. 7. g Department of Gastroenterology and Metabolism , Institute of Biomedical and Health Sciences, Hiroshima University , Hiroshima , Japan. 8. h Laboratory for Digestive Diseases , RIKEN Center for Integrative Medical Sciences , Hiroshima , Japan.
Abstract
BACKGROUND AND AIM: Soluble CD 163 (sCD163) is released from activated liver macrophages in chronic viral hepatitis C (HCV) and serum levels reflect liver disease severity. The impact of direct-acting antiviral (DAA)-therapy on sCD163-levels and the ability of sCD163 to predict the presence of liver fibrosis remain unclear. In a combined observational and prospective study, we aimed to investigate changes in sCD163 with DAA-treatment, to investigate associations between sCD163 and histopathological activity and fibrosis and to validate the sCD163-based fibrosis score in HCV-patients. METHODS: We examined three groups of patients: an Australian (n = 28) treated with pegylated-interferon and a first-generation DAA, a Danish (n = 38) treated with sofosbuvir-based DAA-regimens and a Japanese (n = 562) assessed for activity and fibrosis (Metavir scoring system) in liver biopsies. Serum sCD163-levels were quantified by ELISA. RESULTS: Thirteen (46%) of the Australian patients achieved sustained virological response (SVR) and only these patients had significant decreases in sCD163-levels (2.7 (95%CI:1.9-3.6) vs. 4.1(2.9-5.7) mg L - 1, p = .008). In the Danish group, 37 (97%) patients achieved SVR at 12-weeks post-treatment with 32% reduction in sCD163-levels (5.0 (4.3-5.8) vs. 7.4 (6.3-8.7), p < .001). The decline was rapid and persisted 12 months after treatment cessation (p < .007). sCD163 levels increased in parallel with inflammatory activity and fibrosis (p < .001). The sCD163-based fibrosis score outperformed established fibrosis scores for significant fibrosis (areas under the receiver operating characteristics curves (AUROCs): 0.79 (0.75-0.83) vs. aspartate aminotransferase to platelet ratio index (APRI) 0.73 (0.69-0.77), Fibrosis-4 (FIB-4) 0.74 (0.70-0.78), p < .001). CONCLUSION: sCD163-levels decline rapidly with successful DAA therapy and are associated with histological inflammatory activity and fibrosis, confirming a key role for macrophages in HCV inflammation and fibrosis and supporting sCD163 as a biomarker of treatment response.
BACKGROUND AND AIM: Soluble CD 163 (sCD163) is released from activated liver macrophages in chronic viral hepatitis C (HCV) and serum levels reflect liver disease severity. The impact of direct-acting antiviral (DAA)-therapy on sCD163-levels and the ability of sCD163 to predict the presence of liver fibrosis remain unclear. In a combined observational and prospective study, we aimed to investigate changes in sCD163 with DAA-treatment, to investigate associations between sCD163 and histopathological activity and fibrosis and to validate the sCD163-based fibrosis score in HCV-patients. METHODS: We examined three groups of patients: an Australian (n = 28) treated with pegylated-interferon and a first-generation DAA, a Danish (n = 38) treated with sofosbuvir-based DAA-regimens and a Japanese (n = 562) assessed for activity and fibrosis (Metavir scoring system) in liver biopsies. Serum sCD163-levels were quantified by ELISA. RESULTS: Thirteen (46%) of the Australian patients achieved sustained virological response (SVR) and only these patients had significant decreases in sCD163-levels (2.7 (95%CI:1.9-3.6) vs. 4.1(2.9-5.7) mg L - 1, p = .008). In the Danish group, 37 (97%) patients achieved SVR at 12-weeks post-treatment with 32% reduction in sCD163-levels (5.0 (4.3-5.8) vs. 7.4 (6.3-8.7), p < .001). The decline was rapid and persisted 12 months after treatment cessation (p < .007). sCD163 levels increased in parallel with inflammatory activity and fibrosis (p < .001). The sCD163-based fibrosis score outperformed established fibrosis scores for significant fibrosis (areas under the receiver operating characteristics curves (AUROCs): 0.79 (0.75-0.83) vs. aspartate aminotransferase to platelet ratio index (APRI) 0.73 (0.69-0.77), Fibrosis-4 (FIB-4) 0.74 (0.70-0.78), p < .001). CONCLUSION: sCD163-levels decline rapidly with successful DAA therapy and are associated with histological inflammatory activity and fibrosis, confirming a key role for macrophages in HCV inflammation and fibrosis and supporting sCD163 as a biomarker of treatment response.
Authors: Rebeca S De Pablo-Bernal; M Reyes Jimenez-Leon; Laura Tarancon-Diez; Alicia Gutierrez-Valencia; Ana Serna-Gallego; Maria Trujillo-Rodriguez; Ana I Alvarez-Rios; Yusnelkis Milanes-Guisado; Nuria Espinosa; Cristina Roca-Oporto; Pompeyo Viciana; Luis F Lopez-Cortes; Ezequiel Ruiz-Mateos Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Victoria Cairoli; Elena De Matteo; Paola Casciato; Beatriz Ameigeiras; María Victoria Preciado; Pamela Valva Journal: PLoS One Date: 2022-07-07 Impact factor: 3.752
Authors: Tea L Laursen; Thomas D Sandahl; Konstantin Kazankov; Jacob George; Henning Grønbæk Journal: World J Gastroenterol Date: 2020-06-14 Impact factor: 5.742
Authors: Jean-Baptiste Gorin; David F G Malone; Benedikt Strunz; Tony Carlsson; Soo Aleman; Niklas K Björkström; Karolin Falconer; Johan K Sandberg Journal: Sci Rep Date: 2020-02-07 Impact factor: 4.379
Authors: Rasmus Hvidbjerg Gantzel; Mikkel Breinholt Kjær; Tea Lund Laursen; Konstantin Kazankov; Jacob George; Holger Jon Møller; Henning Grønbæk Journal: Front Med (Lausanne) Date: 2021-01-08
Authors: Lars Bossen; Mette Vesterhus; Johannes R Hov; Martti Färkkilä; William M Rosenberg; Holger J Møller; Kirsten M Boberg; Tom H Karlsen; Henning Grønbæk Journal: Clin Transl Gastroenterol Date: 2021-03-01 Impact factor: 4.396